

INTRODUCTION

Chronic hepatitis C (HCV) is a primary risk factor for hepatocellular carcinoma (HCC), typically associated with advanced fibrosis and cirrhosis. However, the development of HCC in non-cirrhotic patients with chronic HCV is exceedingly rare, occurring in less than 1.5% of cases. We present a case series highlighting two instances of HCC in non-cirrhotic HCV patients..

CASE 1

A 67-year-old male with a history of chronic myeloid leukemia (CML) in remission and treatment-naïve chronic HCV (genotype 1b) was referred for HCV treatment. Imaging revealed five LIRADS-5 liver lesions and liver biopsy confirmed mild portal fibrosis without septa (F1) and moderately differentiated HCC. The patient underwent hepatic resection followed by successful HCV treatment.




Figure 1: HE show Polygonal cells with nuclear atypia, including high N/C ratio, irregular nuclear membrane, multinucleation and prominent nuclei(scanning lower power)




Figure 2: HE show polygonal cells with nuclear atypia, including high N/C ratio, irregular nuclear membrane, multinucleation and prominent nuclei(scanning higher power)




Figure 3: A reticulin stain performed highlights the thickened hepatocyte plates (> 3 cell thick) supports the diagnosis of hepatocellular carcinoma (scanning higher power).




Figure 4: A reticulin stain performed highlights the thickened hepatocyte plates (> 3 cell thick) supports the diagnosis of hepatocellular carcinoma (scanning lower power).




Figure 5: HE staining show periportal fibrosis, focal bridging and lymphocytes infiltration (scanning power).

CASE 2

A 69-year-old male with chronic HCV (genotype 3) achieved sustained virological response (SVR) four years prior, and presented with two LIRADS-5 liver lesions. A liver biopsy revealed mild portal fibrosis without septa (F1) and confirmed HCC. Yttrium-90 radioembolization was performed with a favorable response.




Figure 6: Liver Reticulin Normal




Figure 7: Liver Biopsy with Inflammation and pathology

DISCUSSION

- Chronic viral infections, particularly hepatitis B (HBV) and hepatitis C (HCV), are leading causes of primary hepatocellular carcinoma (HCC).
- HBV can cause HCC in non-cirrhotic individuals due to its ability to integrate with the host genome, leading to cell cycle dysregulation.
- HCV, being an RNA virus, cannot integrate with host DNA but can promote hepatocyte immortalization, potentially leading to HCC.
- Alcohol use, toxin exposure, and cirrhosis are major risk factors for HCC development.
- Rare cases of HCC in non-cirrhotics with HBV have been reported, while HCC in non-cirrhotics with chronic HCV is less common.
- Some cases of HCC in non-cirrhotics occur after achieving sustained virologic response (SVR) post-HCV treatment.
- The incidence of HCC in non-cirrhotic HCV patients is low but not negligible.
- Co-infection with HBV could contribute to HCC development in non-cirrhotics, although ruled out in the presented cases.
- Retrospective studies have shown a higher prevalence of HCC in non-cirrhotics with chronic HCV infection, especially among men.
- Screening guidelines post-HCV treatment in non-cirrhotics vary, with some advocating for routine screening in certain risk groups to detect HCC early.
- Latest guidelines (as of 2023) may not recommend routine follow-up for non-cirrhotic patients post-HCV treatment unless they have specific risk factors.
- Small sample size notwithstanding, the presence of Lirads-5 lesions in the presented cases adds to the understanding of HCC in non-cirrhotics.

CONCLUSION

The possibility of developing HCC in non-cirrhotic HCV patients even without advanced fibrosis raises the question regarding the need to perform closer screening/follow-up of these patients, even after SVR. Further studies with considerations given to genotype and gender to confirm these findings are needed.

REFERENCES

1. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. *J Clin Gastroenterol.* 2013 Jul;47 Suppl(0):S2-6. doi: 10.1097/MCG.0b013e3182872f29. PMID: 23632345; PMCID: PMC3683119.
2. Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, Chen DS. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. *J Infect Dis.* 2006 Sep 1;194(5):594-9. doi: 10.1086/505883. Epub 2006 Jul 18. PMID: 16897657.
3. Ray RB, Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. *Virology.* 2000 May 25;271(1):197-204. doi: 10.1006/viro.2000.0295. PMID: 10814584.
4. Lewis S, Roayaie S, Ward SC, Shykevsky I, Jibara G, Taouli B. Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis. *AJR Am J Roentgenol.* 2013 Jun;200(6):W610-6. doi: 10.2214/AJR.12.9151. PMID: 23701091.
5. Shrager B, Jibara G, Schwartz M, Roayaie S. Resection of hepatocellular carcinoma without cirrhosis. *Ann Surg.* 2012 Jun;255(6):1135-43. doi: 10.1097/SLA.0b013e31823e70a3. PMID: 22258064.
6. Nash KL, Woodall T, Brown AS, Davies SE, Alexander GJ. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis. *World J Gastroenterol.* 2010 Aug 28;16(32):4061-5. doi: 10.3748/wjg.v16.i32.4061. PMID: 20731020; PMCID: PMC2928460.
7. Mattos AA, Marcon Pdos S, Araújo FS, Coral GP, Tovo CV. HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT. *Rev Inst Med Trop Sao Paulo.* 2015 Dec;57(6):519-22. doi: 10.1590/S0036-46652015000600011. PMID: 27049708; PMCID: PMC4727140.
8. Yeh MM, Daniel HD, Torbenson M. Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. *Mod Pathol.* 2010 Feb;23(2):276-83. doi: 10.1038/modpathol.2009.174. Epub 2009 Nov 20. PMID: 19935643; PMCID: PMC3037012.
9. Debika Bhattacharya, Andrew Aronsohn, Jennifer Price, Vincent Lo Re, the American Association for the Study of Liver Diseases–Infectious Diseases Society of America HCV Guidance Panel , Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America